David Brunel

Chairman at AmideBio

📍 Boulder, Colorado, United States🔄 Updated October 2026💼 4 investments📅 36 years investing🗓 Last invested Sep 2021
VC🌍 United States
4
Total investments
0
Early stage
0
Mid stage
1
Late stage
36y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Sep 2021
Velocity Sciences specializes in the directed evolution of RNA aptamers (high performance aptamers or HPAs) as well as the synthesis of any RNA molecule or construct for use in many applications, with a primary focus on therapeutics.
Investor
2008
UCOPIA, the European leader in Wi-Fi connectivity, aims to capitalize on the great potential of wireless networks to transform the way of working, collaborating, communicating, learning and entertaining. Founded in 2002, the French company has reinvented itself to meet the demands of the markets and impose its vision of the customer experience as a guideline in the evolution of its products and services. With more than 15 years of experience in Wi-Fi access security, profiles and logs management, UCOPIA is a recognized partner for its expertise. But, beyond this technical know-how, UCOPIA wants to transform the use of the Wi-Fi network to better meet the expectations of current users. Thanks to the technology and feedback of our customers, UCOPIA transforms the Wi-Fi network into a local media to enrich the customer experience by sharing the right information to the right person, at the right moment and in the right place. Based on an analytics solution, a true qualified data source, you can enrich your CRM tools to improve the knowledge of your visitors. UCOPIA's solutions and services are aimed at different market segments including companies - from SMEs to major accounts - retail, healthcare, large public places, education or the hotel industry.
Experience · 4 entries
All (4)
Investments (4)
Board (3)
2021
Board Member
Sep 2021
Velocity Sciences specializes in the directed evolution of RNA aptamers (high performance aptamers or HPAs) as well as the synthesis of any RNA molecule or construct for use in many applications, with a primary focus on therapeutics.
2019
Board Member
Jun 2019
Consultative solutions for single-cell, high resolution cytogenetic analysis to enable today’s most innovative developments in cell and gene therapy.
2008
Investor
2008
UCOPIA, the European leader in Wi-Fi connectivity, aims to capitalize on the great potential of wireless networks to transform the way of working, collaborating, communicating, learning and entertaining. Founded in 2002, the French company has reinvented itself to meet the demands of the markets and impose its vision of the customer experience as a guideline in the evolution of its products and services. With more than 15 years of experience in Wi-Fi access security, profiles and logs management, UCOPIA is a recognized partner for its expertise. But, beyond this technical know-how, UCOPIA wants to transform the use of the Wi-Fi network to better meet the expectations of current users. Thanks to the technology and feedback of our customers, UCOPIA transforms the Wi-Fi network into a local media to enrich the customer experience by sharing the right information to the right person, at the right moment and in the right place. Based on an analytics solution, a true qualified data source, you can enrich your CRM tools to improve the knowledge of your visitors. UCOPIA's solutions and services are aimed at different market segments including companies - from SMEs to major accounts - retail, healthcare, large public places, education or the hotel industry.
1990
Ardent/Unidata
COO/CEO/Board member
1990
Investment activity
1990–2021 · 4 investments
19901200812019120211
Recent (last 2 years)Earlier